thumb
April 28, 2021

Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab)

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its supplemental Biologic License Application (sBLA) for a new subcutaneous (SC) route of

thumb
April 20, 2020

Biogen Releases 2019 Corporate Responsibility Report Demonstrating Continuous Progress Across Environmental, Social and Governance Metrics

Continued to improve absolute environmental performance across energy, water and waste metrics while growing the business in 2019; has remained carbon neutral for six years in a row Advanced health equity and diversity goals; 46% of Biogen’s director-level positions and above are held by women

thumb
April 16, 2020

Biogen, Broad Institute of MIT and Harvard, Partners HealthCare Launch Consortium to Build and Share a COVID-19 Biobank

Biogen employees, family members, and other close contacts can contribute blood samples and medical data to aid efforts to rapidly understand and overcome COVID-19 Biobank to provide scientists with access to a large collection of biological and medical data to advance knowledge and search for

thumb
April 8, 2020

Biogen to Report First Quarter 2020 Financial Results April 22, 2020

Cambridge, Mass.— Biogen Inc. (Nasdaq:BIIB) today announced it will report first quarter 2020 financial results Wednesday, April 22, 2020, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET.

thumb
April 2, 2020

Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study

DEVOTE will evaluate the safety and potential for even greater efficacy of a higher dose of SPINRAZA in the treatment of spinal muscular atrophy (SMA) Well-established safety profile and proven efficacy of SPINRAZA in a broad range of patients supports exploration of the higher dose Biogen

thumb
March 30, 2020

Biogen to Webcast Encore Aducanumab Presentation From Virtual AAT-AD/PD Meeting on April 2, 2020

Cambridge, Mass. – March 30, 2020 – Biogen (Nasdaq: BIIB) today announced it will host a webcast of its encore presentation related to its Alzheimer’s disease investigational therapy, aducanumab, at the upcoming virtual AAT-AD/PDTM focus meeting. The data in this presentation were previously

thumb
March 16, 2020

Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World

Most of the funds will be directed to support the global response and the immediate needs of communities hardest hit by COVID-19 CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Biogen Inc . (Nasdaq: BIIB) today announced that the Biogen Foundation has committed $10 million to support global

thumb
February 27, 2020

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases

Broad collaboration for gene regulation therapies in neurology, initially focused on development of ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, and a neuromuscular target, with exclusive rights for nine additional undisclosed

thumb
February 24, 2020

Biogen to Present at the Cowen 40th Annual Health Care Conference

Cambridge, MA, - - Biogen Inc.  (Nasdaq: BIIB) announced today that it will present at the Cowen 40th Annual Health Care Conference. The webcast will be live on Monday, March 2, at 11:20 a.m. ET. To access the live webcast, please visit Biogen’s Investors section at www.biogen.com/investors .

thumb
January 13, 2020

Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc.

PF-05251749 is a CNS-penetrant regulator of circadian rhythm with potential to address behavioral and neurological symptoms across various psychiatric and neurological diseases   Biogen to pay Pfizer $75 million upfront plus potential milestones of up to $635 million, and royalties   PF-05251749

thumb
December 18, 2019

Biogen to Report Fourth Quarter and Year-End 2019 Financial Results January 30, 2020

Cambridge, MA, - - Biogen Inc.  (Nasdaq: BIIB) today announced it will report fourth quarter and year-end 2019 financial results Thursday, January 30, 2020, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at